2012 Ann Schreiber Grant Recipient – Ngai Na Co, PhD
Ngai Na Co, PhD
MD Anderson Cancer Center
The Role of Stromal microRNA 21 in Omental Ovarian Cancer Progression
Ovarian cancer most frequently metastasizes to the omentum, a major site of intra-abdominal fat in post-menopausal women. This proposal seeks to characterize how the omental adipocytes (fat cells) and fibroblasts (support cells) recruit ovarian tumor cells to the omentum and facilitate the spread of this deadly disease. Our preliminary data suggest that specific, two-way communication occurs between ovarian cancer cells and omental fat and fibroblast cells that not only promotes tumor growth and metastasis in the omentum, but also confers chemoresistance to the tumor cells. We have identified a regulatory molecule, miR-21, that is transferred specifically from omental to ovarian tumor cells. We speculate miR-21 plays an important role in promoting the aggressive behavior of metastatic ovarian cancer, and will characterize its effects on the ability of ovarian cancer cells to invade other tissues and resist the effects of chemotherapy.
The identification of direct mechanisms of communication between omental cells and tumor cells, which promote aggressive tumor behavior, suggests that the development of drugs that interrupt this intracellular communication may prove clinically useful as a strategy to prevent ovarian tumor progression and improve outcomes for obese cancer patients.
Dr. Co is currently a postdoctoral fellow in the Department of Gynecologic Oncology and Reproductive Medicine at the University of Texas MD Anderson Cancer Center. She obtained her Ph.D. degree at the Chinese University of Hong Kong in 2009 during which she investigated the function of a novel oncogene AF1q in human cancer cells. Her research interests include understanding the molecular mechanism underlying obesity on gynecologic tumor risk, the communication between ovarian cancer cells and their microenvironment through microvesicle exchange, and the functional roles of stromal cells on modulating ovarian tumor progression. She is the recipient of the Scholar-in-Training Award from the American Association of Cancer Research in 2011 and 2012.
The five-year survival rate for ovarian cancer has increased by only 8% in the last 30 years.
We are at a critical crossroads for supporting research into unlocking the mysteries of ovarian cancer. You can make a difference by supporting the research of the Ovarian Cancer Research Fund.
Help us find a cure for ovarian cancer. Donate online and make a difference.